Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Debt / NOTE 2.500% 3/1
-
Market price (% of par)
-
114.27%
-
Total 13F principal
-
$574,937,600
-
Principal change
-
+$22,051,000
-
Total reported market value
-
$656,979,517
-
Number of holders
-
44
-
Value change
-
+$27,474,461
-
Number of buys
-
21
-
Number of sells
-
26
Institutional Holders of BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 as of Q1 2025
As of 31 Mar 2025,
BRIDGEBIO PHARMA INC - NOTE 2.500% 3/1 was held by
44 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$574,937,600
in principal (par value) of the bond.
The largest 10 bondholders included
Weiss Asset Management LP, Linden Advisors LP, BRAIDWELL LP, WOLVERINE ASSET MANAGEMENT LLC, Graham Capital Management, L.P., TENOR CAPITAL MANAGEMENT Co., L.P., Point72 Asset Management, L.P., BNP PARIBAS FINANCIAL MARKETS, 683 Capital Management, LLC, and Opti Capital Management, LP.
This page lists
44
institutional bondholders reporting positions
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.